Jupiter Wellness JUPW to offer clinical research services with acquisition of Ascent Clinical Research
Health and Wellness NASDAQ Brand Hires Senior Project Manager: Jupiter Wellness, Inc. (NASDAQ: JUPW)
Developer of CBD-based treatments for multiple skincare applications.
New e-commerce and marketing team with experienced industry veterans.
The JW-300 treatment has been shown to be effective in developing burns (sunburn) in a clinical trial.
Acquisition of Ascent Clinical Research adding $3 million in annual revenue plus contribution to EBITDA.
Exclusive worldwide rights to patented anti-shark technologies.
A new combination treatment with cannabidiol and aspartame significantly reduces the ISGA score in atopic dermatitis.
Exclusive worldwide rights to unique formulas treating Jellyfish and Man O’ War stings, sea lice and swimmer’s itch with 4 patents pending.
Clinical trial of JW-200 for the treatment of actinic keratosis.
$5.0 million share buyback program.
JUPW has announced that Paul Jones has joined Jupiter Wellness as Senior Project Manager.
Paul joins Jupiter Wellness with over 20 years of experience building and leading operations, implementing improvements and overseeing projects across a wide range of industries.
Most recently, he was a project manager at an investment and management firm operating in South Florida and Italy. He was responsible for initiating projects in the United States and Italy, managing costs, schedules and project performance from initiation to completion.
From 2004 to 2011, he was part of the project management team at Ferrari headquarters in Maranello, Italy, where he led the design and production team for Ferrari and Maserati.
“We are extremely excited to add someone of Paul’s caliber to Jupiter’s wellness team. With our rapid growth, he will be an integral part of our team managing and maximizing our product portfolio for both consumer products and new products in scientific development,” said Dr. Glynn Wilson, CSO and President.
Jupiter Wellness, Inc. (NASDAQ: JUPW) is a leading developer of cannabidiol (CBD) therapeutic and medical wellness products. The JUPW clinical pipeline of prescription CBD-enhanced skin care therapeutics addresses indications such as eczema, burns, herpetic cold sores, and skin cancer. JUPW generates revenue from a growing line of exclusive over-the-counter skincare products, including its flagship CaniSun™ sunscreen and other wellness brands.
JUPW showcased its JW-300, a topical cannabidiol treatment for first-degree burns, at the SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology conference held May 11-15, 2022 in Nashville.
The results demonstrate the potential of JW-300 as a prescription or over-the-counter topical cream to help prevent sunburn and its consequences, including skin cancer.
On April 27, JUPW announced that it had entered into an asset purchase agreement with Ascent Clinical Research, Inc. whereby it acquired certain clinical assets, including clinical trial research contracts worth $3 million. dollars in annual revenue for a purchase price of 5% future net revenue royalties. generated by assets. This asset purchase agreement adds immediate revenue to JUPW in Q2 2022 and positively contributes to EBITDA with no upfront payment or stock acquisition cost.
On April 18, JUPW announced that it had appointed three sales and marketing executives to its team.
JUPW has built a portfolio of award-winning wellness brands including CaniSun, fitCBD, Jack, Wellness CBD 1937, Black Belt CBD and Felix Ambrosia, as well as prescription therapeutics such as Photosil which have been featured in numerous media outlets including the Today Show, CNN, ABC, CBS, Animal Planet, AdWeek, Bloomberg, The Washington Post, Vogue, BuzzFeed and Forbes. As JUPW continues to expand portfolio of clinically tested, science-backed wellness, over-the-counter and prescription products, new marketing team poised to drive revenue
Mohammed Ahmed is an experienced marketing professional specializing in market research, consumer behavior, social media marketing and demand generation.
Jennifer Canon is a research, development, and marketing specialist in the personal care, over-the-counter drug, prescription pharmaceutical, and topical care products industries at companies such as Hydron Technologies and Greyson International. she co-founded.
Guy Shapira is a seasoned digital marketer of nutraceutical, health and beauty products and services.
Watch the Discovery Channel videos on anti-shark technology here: https://youtu.be/Hqp04gdAXyk and here: https://youtu.be/PM0YTlbx1qg
On April 7, JUPW announced the upcoming launch of CaniSun for Shark Defense™, the latest addition to the company’s line of reef-friendly sunscreens. Through a licensing agreement with Shark Defense Technologies LLC, the leading researcher in chemical, electrochemical and magnetic shark repellents, JUPW owns the exclusive worldwide rights to the patents, formulas and production methods of the shark repellent technologies. for use in sunscreen and skin care products.
On April 6, JUPW announced the publication of the results of a clinical study to investigate the safety and efficacy of JW-100, its proprietary lotion formulation for the treatment of atopic dermatitis (eczema) in the Journal of Cosmetic. Dermatology, Vol. 21, number 4, April 2022, pages: 1647-1650.
On April 5, JUPW announced the launch of NoStingz, an exclusive line of sunscreens designed to protect against jellyfish and man-of-war stings, sea lice and swimmer’s itch while continuing to protect the skin. ocean lovers against UVA/UVB in a range of SPF. JUPW has signed a licensing agreement with Shark Defense Technologies for exclusive worldwide intellectual property rights to formulas and production methods for jellyfish protective compounds, including 4 patents pending. The agreement provides for future collaboration to develop and refine additional formulas.
To learn more about the JUPW NoStingz product or to purchase, visit: https://canisun.com/shop/nostingz-your-barrier-of-protection-from-sun-sea/
On February 18, JUPW announced that it had completed enrollment in its clinical trial of JW-200 for the treatment of actinic keratosis (AK), a common form of precancerous growths that typically appear as thick scaly lesions on the skin. exposed to the sun. If left untreated, up to 15.1% of patients with 10 or more AK lesions will develop keratinocyte carcinoma.
On January 25, JUPW announced that its board of directors had approved a $5.0 million stock repurchase program that expires on June 30, 2022. Under the stock repurchase program, common stock of JUPW may be repurchased periodically on the open market or in privately negotiated transactions.
For more information about Jupiter Wellness, Inc. (JUPW), visit www.jupiterwellnessinc.com or https://finance.yahoo.com/news/jupiter-wellness-offer-clinical-research-123000618.html
DISCLAIMER: Products mentioned are THC-free and/or Farm Bill 2018 compliant.
This article is for informational purposes only and does not constitute a recommendation to buy or sell stocks.
Company Name: Jupiter Wellness, Inc.
Contact person: Brian John, CEO
E-mail: Send an email
Call: 561 244 7100
Address:725 North Highway A1A, Suite C-106
State: FL 33477
Country: United States
Website: https://jupiterwellness.com/jupiter-wellness-inc-nasdaq-jupw-is-set-to-offer-clinical-research-services-with-the-3-million-dollar-acquisition-of-acquired-ascent- clinical research/